Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
Senderowicz
A M
AM
National Cancer Institute, National institutes of Health, Bethesda, Maryland, USA.
Vitetta
E
E
Headlee
D
D
Ghetie
V
V
Uhr
J W
JW
Figg
W D
WD
Lush
R M
RM
Stetler-Stevenson
M
M
Kershaw
G
G
Kingma
D W
DW
Jaffe
E S
ES
Sausville
E A
EA
D000328:Adult; D015703:Antigens, CD / Q000276:immunology*; D000944:Antigens, Differentiation, B-Lymphocyte / Q000276:immunology*; D015815:Cell Adhesion Molecules; D005260:Female; D005922:Glomerulonephritis, IGA / Q000601:surgery; D004854:Herpesvirus 4, Human; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D037102:Lectins; D016393:Lymphoma, B-Cell / Q000628:therapy* / Q000821:virology; D011183:Postoperative Complications / Q000276:immunology*; D012276:Ricin / Q000627:therapeutic use*; D012307:Risk Factors; D051918:Sialic Acid Binding Ig-like Lectin 2
D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; C497867:CD22 protein, human; D015815:Cell Adhesion Molecules; D000922:Immunotoxins; D037102:Lectins; D051918:Sialic Acid Binding Ig-like Lectin 2; D012276:Ricin